Assessment of patient-reported outcomes (PROs): treatment satisfaction, medication adherence, and quality of life (QoL) and the associated factors in postmenopausal osteoporosis (PMO) patients in Korea

Dong Won Byun, Seong Hwan Moon, Tak Kim, Hae Hyeog Lee, Hyoung Moo Park, Moo Il Kang, Yong Chan Ha, Ho Yeon Chung, Byung Koo Yoon, Tae Young Kim, Soo Uk Chae, Chan Soo Shin, Kyu Hyun Yang, Jae Hyup Lee, Jae Suk Chang, Sung Hoon Kim, In Joo Kim, Jung Min Koh, Jung Hwa Jung, Kyong Wook YiJeong Joon Yoo, Dong Jin Chung, Young Kyun Lee, Hyun Koo Yoon, Seongbin Hong, Deog Yoon Kim, Ki Hyun Baek, Hyun Joo Kim, Young Joo Kim, Seongsik Kang, Yong Ki Min

    Research output: Contribution to journalArticlepeer-review

    10 Citations (Scopus)


    Patient-reported outcomes (PROs) provide practical guides for treatment; however, studies that have evaluated PROs of women in Korea with postmenopausal osteoporosis (PMO) are lacking. This cross-sectional, multi-center (29 nationwide hospitals) study, performed from March 2013 to July 2014, aimed to assess PROs related to treatment satisfaction, medication adherence, and quality of life (QoL) in Korean PMO women using osteoporosis medication for prevention/treatment. Patient demographics, clinical characteristics, treatment patterns, PROs, and experience using medication were collected. The 14-item Treatment Satisfaction Questionnaire for Medication (TSQM) (score-range, 0–100; domains: effectiveness, side effects, convenience, global satisfaction), Osteoporosis-Specific Morisky Medication Adherence Scale (OS-MMAS) (score-range, 0–8), and EuroQol-5 dimensions questionnaire (index score range, − 0.22 to 1.0; EuroQol visual analog scale score range, 0–100) were used. To investigate factors associated with PROs, linear (treatment satisfaction/QoL) or logistic (medication adherence) regression analyses were conducted. A total of 1804 patients (age, 62 years) were investigated; 60.1% used bisphosphonate, with the majority (67.2%) using weekly medication, 27.8% used daily hormone replacement therapy, and 12.1% used daily selective estrogen receptor modulator. Several patients reported gastrointestinal (GI) events (31.6%) and dental visits due to problems (24.1%) while using medication. Factors associated with the highest OS-MMAS domain scores were convenience and global satisfaction. GI events were associated with non-adherence. TSQM scores for effectiveness, side effects, and GI risk factors were significantly associated with QoL. Our study elaborately assessed the factors associated with PROs of Korean PMO women. Based on our findings, appropriate treatment-related adjustments such as frequency/choice of medications and GI risk management may improve PROs.

    Original languageEnglish
    Pages (from-to)563-572
    Number of pages10
    JournalJournal of Bone and Mineral Metabolism
    Issue number3
    Publication statusPublished - 2019 May 15

    Bibliographical note

    Funding Information:
    This research was sponsored by Pfizer.

    Publisher Copyright:
    © 2018, The Japanese Society for Bone and Mineral Research and Springer Japan KK, part of Springer Nature.


    • Gastrointestinal events
    • Medication adherence
    • Postmenopausal osteoporosis
    • Quality of life
    • Treatment satisfaction

    ASJC Scopus subject areas

    • Endocrinology, Diabetes and Metabolism
    • Orthopedics and Sports Medicine
    • Endocrinology


    Dive into the research topics of 'Assessment of patient-reported outcomes (PROs): treatment satisfaction, medication adherence, and quality of life (QoL) and the associated factors in postmenopausal osteoporosis (PMO) patients in Korea'. Together they form a unique fingerprint.

    Cite this